What is Delcath Systems, Inc. (DCTH) stock price today?

Delcath Systems, Inc. (DCTH) is currently trading at $15.36, up 2.13% today.

What is DCTH P/E ratio?

Delcath Systems, Inc.'s P/E ratio is 1375.45. This is above the market average, reflecting high growth expectations.

What is DCTH return on equity (ROE)?

Delcath Systems, Inc.'s return on equity (ROE) is 0.46%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Delcath Systems, Inc.'s market cap?

Delcath Systems, Inc. has a market capitalization of $530.25M.

NASDAQ · Medical - Devices

Delcath Systems, Inc. (DCTH) Stock

$15.36 +2.13% NASDAQ: DCTH Healthcare

Valuation

Metric	Value
Price	$15.36
Market Cap	$530.25M
P/E Ratio	1375.45
P/B Ratio	4.48
P/S Ratio	5.47
EPS (TTM)	$0.00
52-Week High	$17.42
52-Week Low	$8.12
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	0.46%
ROA	0.39%
ROCE	-1.47%
Gross Margin	0.00%
Operating Margin	1.18%
Net Margin	0.56%
Debt/Equity	0.02
Current Ratio	10.91

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$4.0M	$3.0M	$2.0M	$37.0M	$85.0M
Operating Profit	$-25.0M	$-34.0M	$-38.0M	$-12.0M	$1.0M
Net Profit	$-26.0M	$-37.0M	$-48.0M	$-26.0M	$3.0M
EPS	$-3.59	$-4.12	$-0.48	$-0.12	$0.07
Op Margin	-690.0%	-1245.0%	-1849.0%	-33.4%	0.8%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$33.0M	$18.0M	$39.0M	$77.0M	$124.0M
Total Liabilities	$21.0M	$24.0M	$23.0M	$8.0M	$12.0M
Cash	$23.0M	$8.0M	$13.0M	$32.0M	$43.0M
Borrowings	$16.0M	$16.0M	$10.0M	$1.0M	$1.0M

Latest News

HEPZATO-KIT Market Forecast to 2034 Highlights Growth Drivers, Sales Potential and Competitive Landscape Across the 7MM GlobeNewswire · Jul 14, 2026 Delcath Systems Doses First Patient in Mid-Stage Trial of Hepzato MT Newswires · Jul 9, 2026 Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer Business Wire · Jul 9, 2026 Delcath (DCTH) Q1 2026 Earnings Transcript Motley Fool · May 8, 2026 Delcath Systems Q1 Earnings Call Highlights MarketBeat · May 7, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-23.0M	$-25.0M	$-31.0M	$-19.0M	$23.0M
Investing Cash Flow	$0	$0	$-20.0M	$-2.0M	$-28.0M
Financing Cash Flow	$2.0M	$0	$35.0M	$43.0M	$-6.0M
Net Cash Flow	$-2.0M	$-15.0M	$1.0M	$20.0M	$11.0M
Free Cash Flow	$-23.0M	$-25.0M	$-31.0M	$-19.0M	$21.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-17.44
EV / EBITDA	281.57
FCF Yield	3.35%
Quick Ratio	8.95
Interest Coverage	0.00
Return 1Y	7.06%
Return 3Y	157.88%
Return 5Y	37.29%

Ownership

Insiders Held8.13%

Institutions Held49.02%

Institutions Float Held53.36%

Institutional Holder	Shares	Report Date
Vanguard Capital Management LLC	1,329,288	2026-03-31
Blackrock Inc.	1,784,466	2026-03-31
Private Wealth Advisors, LLC	591,524	2026-03-31
Rosalind Advisors, Inc.	3,300,389	2026-03-31
Propel Bio Management, LLC	979,698	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$336.64	-1.11%	38.93	$4.94T	0.32%
MSFTMicrosoft Corporation	$535.07	+2.38%	28.68	$3.97T	0.76%
GOOGLAlphabet Inc.	$351.66	+0.97%	16.94	$4.26T	0.26%
AMZNAmazon.com, Inc.	$262.43	+3.29%	19.82	$2.82T	0.00%
METAMeta Platforms, Inc.	$718.67	-0.31%	27.93	$1.83T	0.28%

About Delcath Systems, Inc.

Delcath Systems, Inc. is led by CEO Gerard J. Michel, employs 96 people, headquartered in US, publicly traded since 2018.

Delcath Systems, Inc. (DCTH) stock trades at $15.36 with a market capitalization of $530.25M. The stock is valued at a price-to-earnings (P/E) ratio of 1375.45, price-to-book of 4.48, price-to-sales of 5.47. Over the past 52 weeks the stock has ranged between $8.12 and $17.42, and currently trades 11.8% below its 52-week high.

On profitability, Delcath Systems, Inc. generates a return on equity (ROE) of 0.46%, return on capital employed of -1.47%, an operating margin of 1.18%, a net profit margin of 0.56%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides